Oncology
The Phase III study’s principal investigator said that if Xpovio doesn’t win approval, NCCN Guidelines could enable off-label use, as has occurred with BMS’s Reblozyl.
The European Medicines Agency is set to adopt opinions on whether marketing approval should be granted to five new products, including three orphans. A decision is also due on a previously-rejected Alzheimer’s drug that was under re-examination.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The company announced Phase I data for varsetatug masetecan in metastatic colorectal cancer, where it sees a significant and largely untapped market.
San Diego-based Onchilles Pharma's neutrophil-derived ELANE pathway agent N17350 targets a universal cancer vulnerability, combining direct tumor killing with immune activation. It is now entering first-in-human trials across solid tumors.
In an interview with Scrip, Samsung Bioepis’ VP and Innovation Project Lead talks about the newly launched innovation project as well as the firm's strategies and goals in ADCs and other novel therapeutics.
As the US biosimilars market continues to evolve, Cardinal Health’s director of biosimilars Dracey Poore talks to Generics Bulletin for an exclusive Q&A.
Merck's post-Keytruda oncology strategy rests on three pillars – immune deepening, tissue targeting and tumor-intrinsic mechanisms – anchored by patient selection, AI-accelerated discovery and a KRAS bet that could define its next era.
Moderna will pay $950m upfront under the settlement, which lifts a significant weight off its shoulders, as investors had feared it could be on the hook for $5bn.
Aqemia uses proprietary physics-based solvers paired with generative AI to discover genuinely novel drug candidates, bypassing historical training data to crack targets others cannot.
Natco and US partner Breckenridge have launched generic pomalidomide in the US, targeting a $3.2bn market. The firms believe they have 180 days of shared exclusivity, strengthening Natco’s oncology portfolio.
Swedish biotech Affibody is using tiny engineered proteins to expand radioligand therapy's target space. CEO David Bejker details its HER2 program, Albumod technology and partnership strategy.